etomoxir has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corbet, C; Deskeuvre, M; Dierge, E; Feron, O; Frédérick, R; Lan, J; Messens, J; Riant, O | 1 |
| Chen, S; Chua, C; Fukawa, T; Ho, YS; Huang, D; Jun-Hao, ET; Kanayama, HO; Lai, JH; Li, Z; Lim, WJ; Mak, SY; Min-Wen, JC; Mohan, RE; Ong, HS; Ong, P; Qian, CN; Shyh-Chang, N; Tan, IB; Tan, KK; Teh, BT; Wang, RR; Yan-Jiang, BC | 1 |
2 other study(ies) available for etomoxir and Neoplasms
| Article | Year |
|---|---|
Targeting cancer cells in acidosis with conjugates between the carnitine palmitoyltransferase 1 inhibitor etomoxir and pH (low) insertion peptides.
Topics: Acidosis; Carnitine O-Palmitoyltransferase; Epoxy Compounds; Humans; Hydrogen-Ion Concentration; Neoplasms; Peptides | 2022 |
Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia.
Topics: Aged; Animals; Blotting, Western; Cachexia; Cell Line; Cell Line, Tumor; Cytokines; Disease Models, Animal; Enzyme Inhibitors; Epoxy Compounds; Fatty Acids; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Male; Metabolomics; Mice; Middle Aged; Muscle Fibers, Skeletal; Muscle, Skeletal; Muscular Atrophy; Neoplasms; Oxidation-Reduction; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Stem Cells | 2016 |